• Теги
    • избранные теги
    • Компании2878
      • Показать ещё
      Разное741
      • Показать ещё
      Страны / Регионы393
      • Показать ещё
      Международные организации44
      • Показать ещё
      Люди107
      • Показать ещё
      Формат38
      Показатели89
      • Показать ещё
      Издания19
      • Показать ещё
Gilead Sciences
22 мая, 16:00

Investing Podcast Highlights: Tech Stocks, Trump, REITs, Retail Earnings, and More!

Investing Podcast Highlights: Tech Stocks, Trump, REITs, Retail Earnings, and More!

22 мая, 15:50

Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose

Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.

Выбор редакции
20 мая, 01:46

Cramer's lightning round: I've got a message for the struggling Gilead Sciences

Jim Cramer shares his take on caller favorite stocks, including this drugmaker.

19 мая, 16:30

Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron

Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron

18 мая, 01:55

Value Stock or Value Trap?

Tracey tells you how not to get fooled by value trap stocks on this week's podcast.

15 мая, 02:48

Reckless stock trading leaves Congress rife with conflicts

After the furor over Tom Price’s investments, four more members quietly bought shares in the same firm.

09 мая, 00:24

4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

08 мая, 16:30

The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric

The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric

Выбор редакции
05 мая, 23:08

Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat

Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.

05 мая, 20:43

Top Research Reports for Today: GILD, DOW, MET & More

Top Research Reports for Today: GILD, DOW, MET & More

Выбор редакции
04 мая, 18:53

Analysts On Gilead: We Think They're Mobilizing For A Deal

Is M&A in the cards for Gilead Sciences, Inc. (NASDAQ: GILD )? Credit Suisse analysts Alethia Young and Eliana Merle think so. In a note reviewing the company's first-quarter results, the analysts said ...

03 мая, 21:58

Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.

Выбор редакции
03 мая, 21:43

After Gilead Earnings, Buy These Biotech Stocks

Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.

Выбор редакции
03 мая, 21:43

After Gilead Earnings, Buy These Biotech Stocks

Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.

03 мая, 17:25

Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates

Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.

03 мая, 16:30

Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day

Alphabet, Boston Beer, Apple and Gilead Sciences highlighted as Zacks Bull and Bear of the Day

03 мая, 14:22

Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update

Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.

03 мая, 09:17

Квартальная прибыль Gilead Sciences не оправдала прогнозов

Американская фармацевтическая компания Gilead Sciences заявила о прибыли в первом квартале, не дотянувшей до средних ожиданий аналитиков Уолл-Стрит. Так, скорректированная прибыль составила $2,23 на одну акцию, хотя аналитики прогнозировали $2,28 на бумагу. Выручка, тем временем, оказалась на уровне $6,51 млрд, что также не дотянуло до ожиданий рынка в $6,63 млрд. Стоит отметить, что компания сохранила прогнозы по выручке на текущий год в пределах $22,5-24,5 млрд. Аналитики, в свою очередь, ожидают годовую выручку в размере $24,73 млрд.

Выбор редакции
03 мая, 00:54

Apple Sells Fewer iPhones, Gilead Misses Sales

Apple, Inc. (AAPL) shares are falling more than 1% in after-market trading following its fiscal Q2 earnings report.